Generic placeholder image

Current Protein & Peptide Science

Editor-in-Chief

ISSN (Print): 1389-2037
ISSN (Online): 1875-5550

Review Article

The Interplay Between Depression and Parkinson´s Disease: Learning the Link Through Ca2+/cAMP Signaling

Author(s): Leandro Bueno Bergantin*

Volume 21 , Issue 12 , 2020

Page: [1223 - 1228] Pages: 6

DOI: 10.2174/1389203721666200206161912

Price: $65

Abstract

Background: Parkinson´s disease (PD) and depression have an interplay at multiple cellular levels, a phenomenon which is translated into clinical data showing that depressive patients presented an enhanced risk for developing PD. The pathogenesis of both diseases is under intensive debate as correlated to dysregulations related to Ca2+ signaling.

Objective: Then, revealing this interplay between these diseases may provide novel insights into the pathogenesis of them.

Methods: Publications involving Ca2+ signaling, PD and depression (alone or combined) were collected by searching PubMed and EMBASE.

Results: Not surprisingly, calcium (Ca2+) channel blockers (CCBs), classical antihypertensive medicines, have been demonstrated off-label effects, such as alleviating both PD and depression symptoms.

Discussion: A mechanism under debate for the antiparkinsonism and antidepressant effects associated to CCBs is focused on the restoration of Ca2+ signaling dysregulations. In addition, previous studies have observed that CCBs can affect Ca2+/cAMP signaling.

Conclusion: Thus, this article discussed the role of Ca2+/cAMP signaling in the interplay between depression and PD, including the implications for the pharmacotherapy involving CCBs.

Keywords: Ca2+/cAMP signaling, depression, Parkinson´s disease, pharmacotherapy, CCBs.

Graphical Abstract
[1]
Salat, D.; Noyce, A.J.; Schrag, A.; Tolosa, E. Challenges of modifying disease progression in prediagnostic Parkinson’s disease. Lancet Neurol., 2016, 15(6), 637-648.
[http://dx.doi.org/10.1016/S1474-4422(16)00060-0] [PMID: 26993435]
[2]
Hayes, M.W.; Fung, V.S.; Kimber, T.E.; O’Sullivan, J.D. Current concepts in the management of Parkinson disease. Med. J. Aust., 2010, 192(3), 144-149.
[http://dx.doi.org/10.5694/j.1326-5377.2010.tb03453.x] [PMID: 20121682]
[3]
Braak, H.; Ghebremedhin, E.; Rüb, U.; Bratzke, H.; Del Tredici, K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res., 2004, 318(1), 121-134.
[http://dx.doi.org/10.1007/s00441-004-0956-9] [PMID: 15338272]
[4]
Gustafsson, H.; Nordström, A.; Nordström, P. Depression and subsequent risk of Parkinson disease: A nationwide cohort study. Neurology, 2015, 84(24), 2422-2429.
[http://dx.doi.org/10.1212/WNL.0000000000001684] [PMID: 25995056]
[5]
Bergantin, L.B.; Caricati-Neto, A. Challenges for the pharmacological treatment of neurological and psychiatric disorders: Implications of the Ca(2+)/cAMP intracellular signalling interaction. Eur. J. Pharmacol., 2016, 788, 255-260.
[http://dx.doi.org/10.1016/j.ejphar.2016.06.034] [PMID: 27349146]
[6]
Bergantin, L.B.; Souza, C.F.; Ferreira, R.M.; Smaili, S.S.; Jurkiewicz, N.H.; Caricati-Neto, A.; Jurkiewicz, A. Novel model for “calcium paradox” in sympathetic transmission of smooth muscles: role of cyclic AMP pathway. Cell Calcium, 2013, 54(3), 202-212.
[http://dx.doi.org/10.1016/j.ceca.2013.06.004] [PMID: 23849429]
[7]
Bergantin, L.B. Neurodegenerative Diseases: Where To Go From Now? Thought Provoking Through Ca2+/cAMP Signaling Interaction. Brain Disord. Ther., 2017, 6e125
[http://dx.doi.org/10.4172/2168-975X.1000e125]
[8]
Bergantin, L.B. Neurological Disorders: Is There a Horizon? Emerging Ideas from the Interaction between Ca2+ and Camp Signaling Pathways. J. Neurol. Disord., 2017, 5e124
[http://dx.doi.org/10.4172/2329-6895.1000e124]
[9]
Caricati-Neto, A.; García, A.G.; Bergantin, L.B. Pharmacological implications of the Ca(2+)/cAMP signaling interaction: from risk for antihypertensive therapy to potential beneficial for neurological and psychiatric disorders. Pharmacol. Res. Perspect., 2015, 3(5)e00181
[http://dx.doi.org/10.1002/prp2.181] [PMID: 26516591]
[10]
Bezprozvanny, I.; Mattson, M.P. Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease. Trends Neurosci., 2008, 31(9), 454-463.
[http://dx.doi.org/10.1016/j.tins.2008.06.005] [PMID: 18675468]
[11]
Caricati-Neto, A.; Bergantin, L.B. Pharmacological modulation of neural Ca2+/camp signaling interaction as therapeutic goal for treatment of Alzheimer’s disease. J. Syst. Integr. Neurosci., 2017, 3.
[http://dx.doi.org/10.15761/JSIN.1000185]
[12]
Caricati-Neto, A.; Bergantin, L.B. The passion of a scientific discovery: the “calcium paradox” due to Ca2+/camp interaction. J. Syst. Integr. Neurosci., 2017, 3.
[http://dx.doi.org/10.15761/JSIN.1000186]
[13]
Caricati-Neto, A.; Bergantin, L.B. From a “eureka insight” to a novel potential therapeutic target to treat Parkinson’s disease: The Ca2+/camp signaling interaction. J. Syst. Integr. Neurosci., 2017, 4.
[http://dx.doi.org/10.15761/JSIN.1000187]
[14]
Bergantin, L.B. Caricati-Neto, A Insight from “Calcium Paradox” due to Ca2+/cAMP Interaction. Novel Pharmacological Strategies for the Treatment of Depression Int Arch Clin Pharmacol, 2016, 2, 7.
[http://dx.doi.org/10.23937/2572-3987.1510007]
[15]
van Hilten, J.J.; Ramaker, C.C.; Stowe, R.; Ives, N.J. Bromocriptine/levodopa combined versus levodopa alone for early Parkinson’s disease. Cochrane Database Syst. Rev., 2002, (2)CD003634
[http://dx.doi.org/10.1002/14651858.CD003634.pub2] [PMID: 17943795]
[16]
Kaster, M.P.; Moretti, M.; Cunha, M.P.; Rodrigues, A.L. Novel approaches for the management of depressive disorders. Eur. J. Pharmacol., 2016, 771, 236-240.
[http://dx.doi.org/10.1016/j.ejphar.2015.12.029] [PMID: 26703867]
[17]
Ritz, B.; Rhodes, S.L.; Qian, L.; Schernhammer, E.; Olsen, J.H.; Friis, S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann. Neurol., 2010, 67(5), 600-606.
[PMID: 20437557]
[18]
Wu, C.L.; Wen, S.H. A 10-year follow-up study of the association between calcium channel blocker use and the risk of dementia in elderly hypertensive patients. Medicine (Baltimore), 2016, 95(32)e4593
[http://dx.doi.org/10.1097/MD.0000000000004593] [PMID: 27512890]
[19]
Bergantin, L.B.; Caricati-Neto, A. Novel concepts for clinical pharmacology from "Calcium Paradox" due to neuronal interaction between signaling pathways mediated by Ca2+ and cAMP: from 1975 to 2017. Int. Arch. Clin. Pharmacol., 2017.
[http://dx.doi.org/10.23937/2572-3987.1510013]
[20]
Bergantin, L.B.; Caricati-Neto, A. Emerging Concepts for Neuroscience Field from Ca2+/cAMP Signaling Interaction. J. Neurol. Exp. Neurosci., 2017, 3(1), 29-32.
[http://dx.doi.org/10.17756/jnen.2017-024]
[21]
Bergantin, L.B. Advances for the pharmacotherapy of depression - Presenting the rising star: Ca2+/camp signaling interaction. J. Syst. Integr. Neurosci., 2017, 3.
[http://dx.doi.org/10.15761/JSIN.1000161]
[22]
Reijnders, J.S.; Ehrt, U.; Weber, W.E.; Aarsland, D.; Leentjens, A.F. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov. Disord., 2008, 23(2), 183-189.
[http://dx.doi.org/10.1002/mds.21803] [PMID: 17987654]
[23]
Arabia, G.; Grossardt, B.R.; Geda, Y.E.; Carlin, J.M.; Bower, J.H.; Ahlskog, J.E.; Maraganore, D.M.; Rocca, W.A. Increased risk of depressive and anxiety disorders in relatives of patients with Parkinson disease. Arch. Gen. Psychiatry, 2007, 64(12), 1385-1392.
[http://dx.doi.org/10.1001/archpsyc.64.12.1385] [PMID: 18056546]
[24]
Jacob, E.L.; Gatto, N.M.; Thompson, A.; Bordelon, Y.; Ritz, B. Occurrence of depression and anxiety prior to Parkinson’s disease. Parkinsonism Relat. Disord., 2010, 16(9), 576-581.
[http://dx.doi.org/10.1016/j.parkreldis.2010.06.014] [PMID: 20674460]
[25]
Fang, F.; Xu, Q.; Park, Y.; Huang, X.; Hollenbeck, A.; Blair, A.; Schatzkin, A.; Kamel, F.; Chen, H. Depression and the subsequent risk of Parkinson’s disease in the NIH-AARP Diet and Health Study. Mov. Disord., 2010, 25(9), 1157-1162.
[http://dx.doi.org/10.1002/mds.23092] [PMID: 20310050]
[26]
Grossman, E.; Messerli, F.H. Effect of calcium antagonists on sympathetic activity. Eur. Heart J., 1998, 19, 27-31.
[27]
Kreye, V.A.; Lüth, J.B. Proceedings: Verapamil-induced phasic contractions of the isolated rat vas deferens. Naunyn Schmiedebergs Arch. Pharmacol., 1975, 287(Suppl.), R43.
[PMID: 1143442]
[28]
Moritoki, H.; Iwamoto, T.; Kanaya, J.; Maeshiba, Y.; Ishida, Y.; Fukuda, H. Verapamil enhances the non-adrenergic twitch response of rat vas deferens. Eur. J. Pharmacol., 1987, 140(1), 75-83.
[http://dx.doi.org/10.1016/0014-2999(87)90636-4] [PMID: 3113986]
[29]
Rae, G.A.; Calixto, J.B. Interactions of calcium antagonists and the calcium channel agonist Bay K 8644 on neurotransmission of the mouse isolated vas deferens. Br. J. Pharmacol., 1989, 96(2), 333-340.
[http://dx.doi.org/10.1111/j.1476-5381.1989.tb11822.x] [PMID: 2466518]
[30]
Xiao, L.; O’Callaghan, J.P.; O’Donnell, J.M. Effects of repeated treatment with phosphodiesterase-4 inhibitors on cAMP signaling, hippocampal cell proliferation, and behavior in the forced-swim test. J. Pharmacol. Exp. Ther., 2011, 338(2), 641-647.
[http://dx.doi.org/10.1124/jpet.111.179358] [PMID: 21566211]
[31]
Sommer, N.; Löschmann, P.A.; Northoff, G.H.; Weller, M.; Steinbrecher, A.; Steinbach, J.P.; Lichtenfels, R.; Meyermann, R.; Riethmüller, A.; Fontana, A. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med., 1995, 1(3), 244-248.
[http://dx.doi.org/10.1038/nm0395-244] [PMID: 7585041]
[32]
Duman, R.S. Depression: a case of neuronal life and death? Biol. Psychiatry, 2004, 56(3), 140-145.
[http://dx.doi.org/10.1016/j.biopsych.2004.02.033] [PMID: 15271581]
[33]
Tully, P.J.; Peters, R.; Pérès, K.; Anstey, K.J.; Tzourio, C. Effect of SSRI and calcium channel blockers on depression symptoms and cognitive function in elderly persons treated for hypertension: three city cohort study. Int. Psychogeriatr., 2018, 30(9), 1345-1354.
[http://dx.doi.org/10.1017/S1041610217002903] [PMID: 29559030]
[34]
Bergantin, L.B. Debating the “bidirectional link” between diabetes and depression through the Ca2+/cAMP signalling: Off-label effects of Ca2+ channel blockers. Pharmacol. Res., 2019, 141, 298-302.
[http://dx.doi.org/10.1016/j.phrs.2019.01.008] [PMID: 30639385]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy